Association Between SGLT2 Inhibitors and DPP ‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses
Authors' conclusion
Neither SGLT2i nor DPP-4i is associated with an increased risk of AP in patients with type 2 diabetes mellitus after accounting for prescription trends.
Study context
- Population
- Patients with T2D prescribed DPP-4i or SGLT2i at least once, January 2018–December 2020, Korean national health insurance claims database
- Participants
- 7,219 acute pancreatitis (AP) cases
- Comparison
- SGLT2i or DPP-4i use in hazard period vs preceding control periods
- Outcome
- AP (ICD-10 K85.x as principal or first additional diagnosis during hospital admission)
- Follow-up
- 30-day hazard period
Methodological detailsnationwide, claims database, conditional logistic regression, nested case-control analysis
- Nationwide
- Claims database
- Conditional logistic regression
- Nested case-control analysis
Main finding
As reported in the abstract
Risk of AP (case-case-time-control analysis)
Adjusted odds ratio (95% CI)
SGLT2i
0.84(0.52–1.35)
DPP-4i
0.93(0.75–1.15)
Observational data: associations, not effects.
Further findings
Risk of AP (nested case-control study), use within 30-day window
| aOR (95% CI) | ||
|---|---|---|
| SGLT2i | 1.05 (0.91–1.21) | |
| DPP-4i | 1.01 (0.94–1.09) | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
Association Between SGLT2 Inhibitors and DPP ‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses. Diabetes Obes Metab. Published 11 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →